Yes, you can stop semaglutide after losing weight, but how you stop matters
By improving insulin sensitivity and reducing appetite, it helps regulate blood sugar, support healthy weight loss, and decrease the risk of cardiovascular and kidney complications.
On April 1, 2026, the FDA approved orforglirpon under the brand name Foundayo to reduce excess body weight and maintain weight reduction long term in: Adults with obesity Adults with overweight and at least one weight-related medical condition Like other GLP-1s for weight loss, orforglipron is also indicated in combination with a reduced-calorie diet and increased physical activity
The mechanism works the same way whether a patient has elevated blood sugar or maintains normal glucose levels, making these drugs equally relevant for weight management across metabolic profiles
GLP-1 agonists reduce appetite and slow gastric emptying, which can lead to lower blood sugar levels, especially when combined with other glucose-lowering agents